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Anti-Mullerian Hormone (AMH) is an ovarian hormone expressed in growing follicles that have undergone recruitment from the
primordial follicle pool but have not yet been selected for dominance. It is considered an accurate marker of ovarian reserve, able to
reflect the size of the ovarian follicular pool of a woman of reproductive age. In comparison to other hormonal biomarkers such as
serum FSH, low intra- and intermenstrual cycle variability have been proposed for AMH.This review summarizes the knowledge
regardingwithin-subject variability, with particular attention onAMH intracycle variability.Moreover the impact of ethnicity, body
mass index, and smoking behaviour on AMH interindividual variability will be reviewed. Finally changes in AMH serum levels
in two conditions of ovarian quiescence, namely contraceptives use and pregnancy, will be discussed. The present review aims at
guiding researchers and clinicians in interpreting AMH values and fluctuations in various research and clinical scenarios.
1. Introduction
Anti-Müllerian Hormone (AMH) is secreted into the circu-
lation by small growing follicles in the ovary, until they have
reached the size at which theymay be selected for dominance
(6–8mm) [1]. Since the cohort of small growing follicles is in
equilibriumwith the total number primordial follicles, serum
AMH levels reflect the ovarian follicular pool [2]. AMH is
therefore considered an accuratemarker of ovarian reserve [3,
4]. Moreover AMH levels vary less across different menstrual
cycles as well as within one menstrual cycle as compared
to other biomarkers of ovarian activity, such as FSH, which
has a number of obvious clinical advantages [4–7]. Indeed,
according to different studies, the measurement of AMH on
a random basis throughout the menstrual cycle is associated
with a very good accuracy when predicting ovarian response
[8–10].
However while first studies reported a very low variability
throughout the menstrual cycle [11–14], a number of more
recent studies [15–17] indicate a reduction of circulating
AMH in the luteal phase, hence raising the question if AMH
should better be measured on a fixed day of the menstrual
cycles to foster standardization and to allow better cross
comparison between individual assessments.
In this review, we shed light on the partly controver-
sial issue of AMH variability, with particular attention on
AMH intracycle variability, that has been recently widely
debated. Moreover we evaluate the impact of ethnicity, BMI,
and smoking behaviour on AMH interindividual variability.
Finally we discussed changes in AMH serum levels in two
conditions of ovarian suppression, namely contraceptives use
and pregnancy.
2. AMH Interindividual Variability
When talking about hormonal stability, two different types
of variability should be considered: the interindividual and
the intraindividual variability. The interindividual variability
of AMH refers to variations in AMH levels between different
subjects and is first of all secondary to a very high variability
in the number of growing follicles within groups of women
of similar age [18–20]. The high interindividual variability in
AMH is not surprising, given the wide variability of ovarian
reserve in women. Generally, high interindividual variability
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Figure 1:The interindividual variability of AMH refers to variations
in AMH levels between different women. The coefficient of vari-
ability of AMH in a sample of 416 women aged 18–50 is 0.81. Gen-
erally, high interindividual variability is a good characteristic for a
hormone when used as discriminatory biomarker in clinical setting
(personal data).
is a good characteristic for a hormone when used as discrim-
inatory biomarker in a clinical setting (Figure 1). Indeed the
high interindividual variability of AMH makes it an ideal
candidate biomarker with which to discriminate patients for
diagnostic, prognostic, and other clinical purposes.
3. Effect of Ethnicity, BMI and Smoking on
AMH Levels
In uni- andmulti-variate analyses, black [21, 22] andHispanic
[21] women exhibit serum AMH levels 25% lower than those
found in Caucasian women of similar age. Furthermore, an
unexpectedly high number of black women has unde-
tectable AMH levels despite relatively young age and regular
menstrual cycles, hence indicating a potential discrepancy
between actual ovarian reserve andwhat is indicated byAMH
measurement in this population (Figure 2). More research
on the underlying biological phenomena and consequences
of this finding is clearly urgently needed. However, this
finding indicates that care should be taken when using AMH
reference values across different ethnicities.
Some papers, even if limited to small numbers of patients,
indicated a negative relationship between BMI and serum
AMH levels [23, 24]. However conflicting results have been
reported by others [18, 25–28]. In a recent large study
performed in a healthy general female population, AMH
was negatively related to BMI, but the relationship was age
dependent [27]. In other words, in women, AMH levels
decreased and BMI increased with age; hence, the relation-
ship between AMH and BMI was only secondary to the
stronger relationship of the two variables with age.
There is clear evidence that smoking may directly accel-
erate ovarian follicular depletion, thereby reducing the age at
menopause [29, 30]. Moreover, smoking has been shown to
altermetabolic path for several hormones including estradiol.













































Figure 2: Measurements of AMH versus age in Caucasian (𝑁 =
232) and African-American women (𝑁 = 200). Total serum con-
centrations of AMH versus age indicate that AMH decreases with
age but is highly variable between women and is more variable
among African-American women. The corresponding correlation
coefficients (𝑅2) and linear equations are shown. Please note how
manyAfrican-Americanwomenhad almost undetectableAMH lev-
els although they were eumenorrhoic (reproduced with permission
from Shuh-Huerta et al. [22]).
relationship between smoking and AMH, with some authors
[31–33] reporting reduced AMH levels in smokers versus
nonsmokers and others [18, 27, 34–36] reporting similar
values in both groups of women. In a more recent study [27],
AMH levels of 416 healthy women, including 99 smokers and
317 nonsmokers, were analyzed. As shown in Figure 3, at any
age, the distribution of smokerswas uniform in all quartiles of
AMH distribution (Figure 3). In other words, in reference to
a given age, a similar number of smoking women had high or
low AMH levels, respectively. Accordingly, the debate on the
impact of smoking on the follicular pool and the circulating
AMH levels has not yet been settled. In conclusion, according
to the published studies, it seems that the variability in
ovarian reserve and secondly ethnicity may largely explain
the high degree of interindividual variability in AMH levels.
4. AMH Intraindividual Variability: Long
Term, Short Term, and Ultrashort Term
The intraindividual variability is indicative of variations in
AMH levels in one single subject and may be secondary to




























Figure 3: Indifferent distribution of serum AMH levels of smokers
(𝑁 = 99) over quartiles of AMH distribution in the general female
population (𝑛 = 416) (reproduced with permission from La Marca
et al. [27]).
true biological variations in levels of circulating AMH in
women.
We propose to distinguish among a long-term variability,
a short-term variability and an ultra-short-term variability.
The first refers to variations in AMH levels that occur year
after year and are indicative of the decline in the ovarian re-
serve of a single woman.The second depends on the monthly
physiologic variability in ovarian function; hence, the short-
term variability may refer to intermenstrual cycle variabili-
ty. The ultra-short-term variability indicates the day-by-day
variability and refers to intramenstrual cycle variability.
In a recent prospective longitudinal study, serum AMH
levels have been measured in healthy young prepubertal girls
(6 to 13 years of age) every 6 months for 3 years and the
mean intraindividual coefficient of variation (CV) for AMH
was reported as 22%. This indicates that circulating AMH
shows—on average—onlyminor fluctuationswithin a limited
time span; thus, a random AMH measurement is likely to
be representative indeed for a given girl [37]. The long, term
variability in adult women has been mainly studied in cross-
sectional studies, with some of them including asmany as 10–
15 thousand patients [18, 27, 38–41]. Overall, the studies are in
good agreement that AMH declines with advancing age with
a pattern that recalls the exponential decay of the primordial
follicular pool [2, 42], which is best described by a quadratic
equation [38].
The intermenstrual cycle variability has been analyzed in
two well conducted prospective studies [14, 43]. Both studies
calculated a similar intraclass coefficient (ICC) which was
0.89. The ICC is the ratio of the interindividual variability
over the total variability. Hence the higher the ICC, the lower
the intraindividual variability. Both studies concluded that
89% of the variation in AMH was due to between-subject
variation, while only 11% of variability was secondary to
individual fluctuation in AMH levels (Figure 4). Further-
more, a recent prospective study reported a correlation of
0.88 between AMH measurements performed on cycle day
2 or 3 in two subsequent cycles in women with regular
spontaneous cycles [44]. AMH showed the highest between-
cycle-correlation within an array of hormones assessed,
including testosterone, FSH, E2, inhibin B, and LH.
A highly debated issue relates to whether AMH signifi-
cantly varies or not throughout the menstrual cycle. Several
studies have suggested that serum AMH levels fluctuate little
during the menstrual cycle, as would be expected from the
evidence that AMH is not secreted by the dominant follicle
or corpus luteum [11–14] (Figure 5). AMH is unique among
the known hormones produced by antral follicles, because
its secretion seems to be only marginally influenced by
gonadotropins and it is dramatically reduced as follicles reach
the full gonadotropin sensitivity. As a consequence, AMH
levels during the follicular phase do not reflect the activity
of the developing large dominant follicle of the month, and
conversely on any time point of the menstrual cycle AMH
levels provide information on the number of small antral
follicle present in the ovary which are available for cyclic
follicular recruitment.
To study the intraindividual variability of AMH, Van
Disseldorp et al. [14] calculated the intraindividual CV in a
reanalyses of a previously published paper [11]. The authors
reported that the intraindividual variability of AMH was
only 13% and, most importantly, when dividing patients into
quintiles according to basal AMH levels, the intraindividual
fluctuations were shown to fall in the same quintile in 72%
of the cases and to cross two quintiles in only 1% of the cases
[14].
In contrast, some authors have noted significant fluc-
tuations within one menstrual cycle [15–17]. A very recent
study found serum AMH levels significantly lower in the
luteal than follicular phase with a variation pattern similar
to pituitary FSH, and the intraindividual variance of AMH
was as high as 80% [17]. However the study was based on a
very small group of subjects (𝑛 = 12), and some of them had
as few as five blood samples throughout an entire menstrual
cycle.Moreover when analyzing values for single patients, the
proposed decline of AMH in the luteal phase was not evident
in 25% of patients (Figure 6), hence raising the questions if
the observed reduction of AMH in the luteal phase might be
simply casual instead due to a biological reason indeed.
In another prospective study including 20 women, serum
AMH levels were shown to fluctuate throughout the men-
strual cycle [16]. In this case, the observed fluctuations were
absolutely random throughout the cycle and not associated to
typical gonadotropin or ovarian steroid patterns. Moreover,
the amplitude was proportional to basal AMH levels: women
with low AMH levels exhibited only minor fluctuations,
whereas women with high basal AMH levels showed rela-
tively higher fluctuations.The author speculated to categorize
AMH pattern in “the ageing ovary pattern” and “the younger
ovary pattern” [16]. In spite of the good quality of the study,
where blood samples were collected from each woman daily
along a whole menstrual cycle, some criticisms have been put
on Roberts paper [45] for the lack of the calculation of the
intraindividual coefficient of variation, which is considered
the optimal analysis for hormonal variability. However, at
bottom line, Sowers et al.’s study [16] indicates in a clear
and convincing way that serum AMH levels vary throughout
the menstrual cycle, that fluctuations may be relevant in
those women with high basal levels, and most importantly
that fluctuations are randomly distributed during the cycle.







1 2 3 4
Cycle number
N = 77














Cycle I Cycle II Cycle III
N = 47
ICC: 0.89 IOT assay
(b)
Figure 4: AMH intermenstrual cycle variability throughout several consecutive menstrual cycles. The reported intraclass coefficient (ICC)
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Figure 5: The AMH variability throughout the menstrual cycle.
AMH appears to be stable (reproduced with permission from (a)
La Marca et al. [12]; (b) Tsepelidis et al. [13]).
The random and noncyclic fluctuations in AMH indicate that
measuring the hormone on a fixed day of the menstrual cycle
would not yield any advantage of a random assessment, for




















Figure 6: Changes in concentration of AMH for 12 women between
the early follicular phase and late luteal phase of the cycle (repro-
duced with permission from Hadlow et al. [17]).
In order to verify the effect of female age on the degree of
AMH fluctuations, a recent study re-evaluated for the third
time the data previously described by Hehenkamp et al. [11]
and Van Disseldorp et al. [14]. In a group of 44 women
between 25 and 46 years of age, the absolute intraindivid-
ual variation of AMH (deltaAMH), that is, the difference
between maximum and minimum serum level throughout
one cycle, was found to be significantly and negatively
associated with age. In other words, younger women had
significantly larger fluctuations in AMH levels than older
women [28]. It may be concluded that in patients with low
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ovarian reserve (usually aged women), AMH fluctuations
have little clinical relevance, while in young patients with
usually high ovarian reserve, fluctuations of AMH might
indeed impact on the discriminatory capability of diagnostic
and predictive tests, respectively [28].
The observed variability in AMH levels may have a lim-
iting effect on the main current application of AMH as a
predictive test in IVF practice. AMH is widely used to predict
the ovarian response and to individualize the treatment
according to this prediction [5, 9, 46, 47]. If AMH values
cross the cut-off values proposed for the ovarian response
categories because of true biological variability in AMH, this
might lead to misclassification and erroneous treatment of
patients. Hence the impact of the documentedAMHvariabil-
ity needs to be tested in a clinical setting on a typical target
population undergoing a clinically relevant predictive testing
scenario.
As reported in detail in several reviews and metanalysis
[5, 48–50], AMH is the best hormonal marker for the pre-
diction of ovarian response in IVF. When using a random
AMHmeasurement in order to prospectively predict ovarian
response to exogenous FSH, correct categorization of 75%
of patients in the three categories poor, normal, or hyper-
responder can potentially be obtained [9]. Accordingly,
although not as stable as thought before, AMH still remains
the most “reliable” ovarian hormone and the best hormonal
predictor of ovarian response to stimulation in IVF, with the
important advantage of being randomly measurable.
5. AMH Serum Levels in Ovarian Quiescence
Induced by OC Intake and Pregnancy
Since AMH production by antral follicles has been consid-
ered to be largely gonadotropin independent, a logical conse-
quence is that pituitary suppression, as occurring with oral
contraceptives (OC) or physiologically during pregnancy,
should not be associated with relevant changes in serum
levels.
A number of studies have been published on the effect of
OC on AMH levels [24, 44, 51–57] and most of the available
evaluations are not prospective. The very few prospective
studies unfortunately limited the analysis to a few observa-
tional months (1 to 4 months) of OC treatment and are thus
potentially and insufficiently informative. OC use has been
reported either to insignificantly influence AMH concentra-
tion [44, 51, 52, 54, 55] or to reduce it significantly [53, 56–58].
A large cross-sectional study compared 180 and 76
twenty-year old OC users and nonusers, respectively, and
found that long-termOCusewas associatedwith a significant
mean reduction in AMH levels by 13% [53].Recently a cohort
study based on 863 healthy women (228 OC users and 504
nonusers) reported that AMH serum levels were 29.8% lower
in OC users than those in nonusers. The reduction in AMH
was more pronounced with increasing duration of hormonal
contraception.However no dose-response relationwas found
between the dose of ethinyl estradiol and the impact on serum
AMH concentration [58].
In a well-conducted prospective study, AMH levels dur-


























Figure 7: Serum AMH at baseline and after 5 and 9 weeks of
administration of contraceptives (reproduced with permission from
Kallio et al. [57]).
months after stopping the OC were assessed. Interestingly, a
mean increase in AMH levels by 30% after cessation of the
OC was found (from a mean of 2.0 ng/mL during OC to a
mean of 2.6 ng/mL two months after the last pill, 𝑃 = 0.001)
[56].
Finally, a small randomized trial recently confirmed
largely these findings [57]. The study population consisted
of 42 healthy women randomized to use for 9 weeks an OC
in the form of either an oral pill (𝑛 = 13), a transdermal
patch (𝑛 = 15), or a vaginal ring (𝑛 = 14). After 9 weeks of
contraceptive use, serum AMH levels decreased significantly
by almost 50% as compared to baseline in all treatment
groups (Figure 7) [57].
This evidence is indicative of a suppressive effect of hor-
monal contraception on circulatingAMH levels, at leastwhen
considering long-term use.Thus, serum AMH concentration
may not retain its accuracy as predictors of the ovarian
reserve in women using hormonal contraceptives for long
time.
Pregnancy is a physiological condition associated with
ovarian suppression because of suppressed endogenous gon-
adotropin release. According to the concept that AMH
reflects the continuous FSH-independent noncyclic growth
of small follicles in the ovary, it would be expected to find
nonrelevant alteration in its levels during pregnancy. Indeed,
an early small cross-sectional study reported unmodified
AMH levels throughout pregnancy [59]. Subsequent studies
reported contradictory results, with some confirming this
finding [60, 61], while others describing a decrease in AMH
levels during pregnancy [62, 63]. It has also been reported
that the decline in AMH during pregnancy is evident when
using the Beckman Coulter but not the DSL assay [63].
However, in the only longitudinal study available (𝑛 = 60),
authors found a significant decrease in AMH levels in the
6 International Journal of Endocrinology
2nd and 3rd trimesters compared to the 1st trimester and the
mean reduction at the end of pregnancy was of about 50%
[64]. This study indicated that during pregnancy, there is a
relative ovarian quiescence and reduced follicularmaturation
with a consequent decrease in the population of follicles
secretingAMH.At the same time, at least part of the observed
reduction in AMH levels during pregnancy could also be
explained by the pregnancy-associated hemodilution and
increased plasma-protein binding.
6. Conclusions
In conclusion, on top of the age related decline in AMH, sig-
nificant fluctuations have been reported for a number of con-
ditions and this has to be taken into account when inter-
preting values in clinical practice. Fluctuations in the men-
strual cycle appear to be random and minor. This suggests
that in clinical practice, AMH can be measured indepen-
dently of the cycle phase. Prolonged ovarian suppression as
induced by physiological or pharmacological interventions
may reduce AMH levels, since the long and profound pitu-
itary gonadotropin suppression is associated with a reduced
number of antral follicles. The exact role of patients’ char-
acteristics, as ethnicity, and some habits, as smoking, on
intra- and interindividual variability of AMH need to be
investigated further.
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